Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Novo Nordisk A/S63 enrolled

Overview

This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Acquired Bleeding Disorder Trauma

Interventions

activated recombinant human factor VIIDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Ages Eligible for Study: 18 Years - 85 Years

Locations (2)

Novo Nordisk Investigational Site

Plainsboro, New Jersey, United States

Novo Nordisk Investigational Site

Mississauga, Canada

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.